EUVIMEDEUVIMED entdecken
Crossref

Myasthenia gravis: What does a pharmacist need to know?

Morgan Marriott, Abbey Schwery, Amy VandenBerg

American Journal of Health-System Pharmacy · 21.02.2023 · 80 (5) · 249-257

DOI: 10.1093/ajhp/zxac343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 14.11.2022. Verfasst von Morgan Marriott und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, and University of Michigan College of Pharmacy, Ann Arbor, MI, USA. Hauptthemen laut MEDLINE: Pharmacists, Myasthenia Gravis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Myasthenia gravis (MG) is not commonly covered in pharmacy school curricula. However, many medications that have been reported to cause exacerbations of MG are among the top 200 most prescribed drugs. The purpose of this therapeutic update is to provide pharmacists with a general understanding of the pathophysiology and treatment of MG and describe common medications with the potential to cause new onset or acute worsening of this disease. Summary MG is an autoimmune disorder in which patients develop autoantibodies to a component of the neuromuscular junction, most frequently the acetylcholine receptor, resulting in impairment of skeletal muscle contraction. Although MG is not highly prevalent, there are up to 60,000 individuals with MG in the US, making it a disease that many pharmacists will likely encounter at least once in their career. Immunosuppressant medications and acetylcholinesterase inhibitors are the mainstays of treatment, although there is limited evidence as to which agents are most efficacious. Medications that activate the immune system, such as immune checkpoint inhibitors, may cause new onset of disease, while those with actions on the neuromuscular junction, such as macrolides and fluoroquinolones, can cause acute worsening of disease.

Conclusion

MG, although not frequently covered in pharmacy school curricula, is a disease state for which it is not uncommon for pharmacists to provide care. Treatment tends to be patient specific, and evidence is often weak. Many medications that cause new onset or worsening of MG are among the most prescribed. Key classes of medications to use with caution include macrolides, fluoroquinolones, β-blockers, and magnesium.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacistsMyasthenia GravisHumansAcetylcholinesteraseNeuromuscular JunctionAnti-Bacterial AgentsFluoroquinolones

Stichwörter der Autor:innen

acetylcholineantibioticsexacerbationmyasthenia gravisneuromuscular

Substanzen

AcetylcholinesteraseAnti-Bacterial AgentsFluoroquinolones

Autor:innen und Institutionen

  • Department of Pharmacy, University of Michigan Health System, Ann Arbor, MI, and University of Michigan College of Pharmacy, Ann Arbor, MI, USA.

Zitieren

APA

Marriott, M., Schwery, A., & VandenBerg, A. (2023). Myasthenia gravis: What does a pharmacist need to know?. American Journal of Health-System Pharmacy, 80(5), 249-257. https://doi.org/10.1093/ajhp/zxac343

Vancouver

Marriott M, Schwery A, VandenBerg A. Myasthenia gravis: What does a pharmacist need to know?. American Journal of Health-System Pharmacy. 2023;80(5):249-257. doi:10.1093/ajhp/zxac343

BibTeX
@article{Marriott2023,
  author = {Marriott, Morgan and Schwery, Abbey and VandenBerg, Amy},
  title = {Myasthenia gravis: What does a pharmacist need to know?},
  journal = {American Journal of Health-System Pharmacy},
  year = {2023},
  volume = {80},
  number = {5},
  pages = {249--257},
  doi = {10.1093/ajhp/zxac343}
}
Kostenlos starten →